Bulletin
Investor Alert

New York Markets After Hours

The Ratings Game Archives | Email alerts

Nov. 29, 2021, 3:08 p.m. EST

Merck stock dives after Citi downgrades on ‘high probability’ that HIV treatment will be abandoned

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)
  • X
    Dow Jones Industrial Average (DJIA)
  • X
    Health Care Select Sector SPDR ETF (XLV)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Merck & Co. Inc. sank Monday, to buck the gains in the health care sector and the broader stock market, after Citi Research backed away from its bullish stance on the drug maker, citing concerns over its HIV and COVID-19 treatments.

The stock /zigman2/quotes/209956077/composite MRK +0.20% fell 5.7% in afternoon trading toward a two-month low. The stock is the biggest decliner among the components of the Dow Jones Industrial Average /zigman2/quotes/210598065/realtime DJIA -1.51% , which ran up 305 points, or 0.9%, and of the SPDR S&P Health Care Select Sector exchange-traded fund /zigman2/quotes/205918244/composite XLV -1.40% , which rallied 0.6%.

The stock has now tumbled 17.6% since closing at a record $90.54 on Nov. 4.

Citi’s Andrew Baum cut his rating to neutral, after being at buy for at least the past 2 1/2 years. He cut this stock price target to $85 from $105.

Baum said his “long-standing” bullish thesis on Merck was based on the “under-appreciation” of the company’s drug pipeline, especially its HIV treatment islatravir, which he expected would offset the coming loss of exclusivity of its blockbuster cancer treatment Ketruda. However, he no longer expects any revenue from islatravir.

“We place a high probability that [Merck] will abandon islatravir development in the next three months given likely high regulatory concerns,” Baum wrote in a note to clients.

Baum said he removed all estimates for islatravir from his financial models, following the company’s announcement earlier this month that a dose-dependent decrease in lymphocyte counts was observed in a Phase 2 trial. He said that suggests its very likely that materially higher doses required would lead to “diverse and unacceptable” adverse events.

On Nov. 18, Merck said it stopped dosing in the trial, and on Nov. 23, the company announced a “temporary pause” in enrollment in the Phase 2 study.

Merck’s stock has shed 9.8% since Nov. 18.

“We expect the diminishing outlook for islatravir to further expedite Merck’s business development efforts,” Baum wrote. “We open a negative catalyst watch on the stock along with today’s report.”

But disappointment over islatravir isn’t Merck’s only problem.

Baum said the clinical profile of Merck’s antiviral to treat COVID-19, Lagevrio, continues to deteriorate, putting estimates for Lagevrio for next year and beyond at “material risk.” He said it was “obvious” to him from inception that Lagevrio would have a risk evaluation and mitigation strategy (REMS) drug safety program required by the Food and Drug Administration because of risk of birth defects.

Don’t miss MarketWatch’s daily “Coronavirus Update” column .

“Since that time, we have learnt that Lagevrio’s efficacy is materially lower than that reported by either monoclonals such as Regeneron’s Ronapreve as well as Pfizer’s Paxlovid (on an interim analysis),” Baum wrote.

He also believes it is likely that resistance will emerge over time to monotherapy Lagevrio usage.

“We expect the FDA to recommend monoclonal antibodies to be preferred therapy in immunocompromised patients in order to reduce the risk of resistance,” Baum wrote.

As a result, he said the FDA could end up limiting Lagevrio approval to only non-vaccinated or immunocompromised patients.”

Merck’s stock has lost 4.3% year to date, while shares of Regeneron Pharmaceuticals Inc. /zigman2/quotes/203149337/composite REGN -0.65% have climbed 36.1% and of Pfizer Inc. /zigman2/quotes/202877789/composite PFE -1.53% have hiked up 44.2%. Meanwhile, the SPDR health care ETF has advanced 17.0% this year and the Dow has gained 15.0%.

/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 81.54
+0.16 +0.20%
Volume: 14.49M
Jan. 18, 2022 4:02p
P/E Ratio
28.79
Dividend Yield
3.38%
Market Cap
$205.56 billion
Rev. per Employee
$660,851
loading...
/zigman2/quotes/210598065/realtime
US : Dow Jones Global
35,368.47
-543.34 -1.51%
Volume: 427.26M
Jan. 18, 2022 4:56p
loading...
/zigman2/quotes/205918244/composite
US : U.S.: NYSE Arca
$ 132.19
-1.88 -1.40%
Volume: 16.47M
Jan. 18, 2022 4:00p
loading...
/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 611.22
-4.02 -0.65%
Volume: 974,767
Jan. 18, 2022 4:00p
P/E Ratio
9.76
Dividend Yield
N/A
Market Cap
$66.18 billion
Rev. per Employee
$1.48M
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 54.11
-0.84 -1.53%
Volume: 35.59M
Jan. 18, 2022 4:03p
P/E Ratio
16.06
Dividend Yield
2.96%
Market Cap
$308.43 billion
Rev. per Employee
$883,274
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.